RecruitingNCT07058961

Study of the Intestinal Microbiota

Study of the Intestinal Microbiota of Patients Admitted to Intensive Care for Severe Brain Injury.


Sponsor

University Hospital, Rouen

Enrollment

100 participants

Start Date

Nov 28, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The intestinal microbiota is the set of numerous microorganisms (between 1012 and 1014 bacteria, viruses, parasites, and non-pathogenic fungi) that live in our digestive tract, mainly in the small intestine and colon. Like a fingerprint, the intestinal microbiota is unique to each individual. However, there is a common core of 15-20 species present in all humans, responsible for the essential functions of the microbiota. Recent techniques for high-throughput sequencing of genetic material and metabolomics (i.e., the global analysis of the elements produced by the microbiota) have made it possible to more precisely describe the relationships between microorganisms and the host and how each influences the functioning of the body. Thus, we now know that the microbiota plays a role in digestive, metabolic, immune, and neurological functions. Certain events will modify the microbiota in a more or less lasting way: illnesses, medical treatments, diet, lifestyle. And these changes to the microbiota can, in turn, influence the body's behavior. As a result, dysbiosis-a quantitative, qualitative, or functional alteration of the microbiota-is a serious avenue for explaining certain pathologies. This topic has become central to biological and medical research, as evidenced by the growing number of scientific publications since the 2010s. Scientists are trying to explore the bidirectional links between dysbiosis and pathologies. They are also trying to explore therapeutic avenues: how to modulate the microbiota to maintain it, bring it closer to, or restore its "normal" configuration to limit the impact of dysbiosis? Research has yielded encouraging results: fecal transplantation (instilling a sample of normal microbiota from the feces of healthy donors into a sick person) or new-generation probiotics with protective biological effects.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Brain-injured patient group: Any adult patient admitted to neurosurgical or surgical intensive care for severe brain injury, traumatic or not, requiring intubation, eligible for indirect calorimetry measurements, and whose expected length of stay is \> 48 hours.
  • Control group: Any adult patient admitted to surgical intensive care for multiple trauma without associated brain injury and/or for shock (hemorrhagic or septic\*) and whose expected length of stay is \> 48 hours.

Exclusion Criteria7

  • Refusal to participate in the study (request of non-opposition from relatives if the patient is unfit)
  • Lack of social security affiliation;
  • Minor patient;
  • Patient under legal protection (guardianship or guardianship);
  • Pregnant woman;
  • Moribund patient or whose expected length of stay is ≤ 48 hours;
  • Contraindication to indirect calorimetry (high FiO2, etc.);

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Services de Réanimation Chirurgicale Et Réanimation Neurochirurgicale

Rouen, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07058961